Dermatology Edition: Top Headlines for Week of October 30, 2023

In this edition, FDA approves Bimzelx for plaque psoriasis; roflumilast foam improves quality of life in patients with seborrheic dermatitis and more. Read the full coverage here:

FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis

Roflumilast foam improves quality of life in patients with seborrheic dermatitis

Opzelura effective, well tolerated in children aged at least 2 years with atopic dermatitis

Treatment for onychomycosis prescribed at only 20% of visits, impacting quality of life

Study: Important to weigh berdazimer gel benefits vs. risks in molluscum contagiosum

References:

Calvi IP, et al. Pediatr Dermatol. 2023;doi:10.1111/pde.15419.

Chu D. et al. Poster. Effect of roflumilast foam 0.3% on quality of life in patients with seborrheic dermatitis: patient-reported outcomes from the STRATUM phase III trial. Presented at: AMCP Nexus; Orlando.

Peck GM, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.6770.

Press Release

Press Release